Ilaris Injection, Solution
Product Images NDC 0078-0734

3 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ilaris (NDC 0078-0734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 Mean C-reactive Protein Levels At The End Of Parts 1, 2 And 3 Of Study 1. (Ilaris 01)

Figure 1 Mean C-reactive Protein Levels At The End Of Parts 1, 2 And 3 Of Study 1. (Ilaris 01)
A line graph depicting mean absolute CRP values (mg/L ± SE) over different study phases for Ilaris (canakinumab) treatment compared to placebo. The x-axis marks study periods including baseline, parts 1 to 3, and end of study. The y-axis shows CRP levels up to 60 mg/L. Solid and dashed lines differentiate CRP changes with Ilaris and placebo treatments, respectively, with a dotted line for the upper normal CRP limit (10 mg/L).*
FDA Label Image

Principal Display Panel – Package Label – 150 mg/vial (Ilaris 02)

Principal Display Panel – Package Label – 150 mg/vial (Ilaris 02)
Packaging label for Ilaris (canakinumab) injection, 150 mg/mL, for subcutaneous use. The label indicates a single-dose vial with instructions to discard unused portions. It is manufactured by Novartis Pharmaceuticals Corporation. The label includes storage instructions, ingredient list, and a barcode with NDC 0078-0734-61.*
FDA Label Image

Figure 2. Kaplan-meier Estimates Of The Probability To Stay Flare-free In Part Ii Of Sjia Study 2 By Treatment (Ilaris 03)

Figure 2. Kaplan-meier Estimates Of The Probability To Stay Flare-free In Part Ii Of Sjia Study 2 By Treatment (Ilaris 03)
A Kaplan-Meier survival estimate chart comparing two groups: ACZ885 and Placebo. The x-axis shows weeks in Part II up to 88 weeks, while the y-axis shows the Kaplan-Meier estimate percentage from 0% to 100%. The graph includes patient numbers at risk at various time points for both groups. The solid line represents ACZ885, and the dashed line represents Placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.